Adaptive Biotechnologies (ADPT) Short term Debt (2023 - 2026)

Adaptive Biotechnologies has reported Short term Debt for 4 years, with the latest figure at $5.8 million in Q1 2026.

• Quarterly Short term Debt rose 188.61% year-over-year to $5.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $5.8 million (up 188.61% YoY) and the FY2025 annual result came in at $4.6 million, up 436.65% from the prior year.
• Short term Debt climbed to $5.8 million in Q1 2026 per ADPT's latest filing, from $4.6 million in the prior quarter.
• Over five years, Short term Debt peaked at $5.8 million in Q1 2026 and troughed at $865000.0 in Q4 2024.
• A 4-year average of $3.1 million and a median of $3.1 million in 2025 frame the typical range for Short term Debt.
• The sharpest annual moves came in 2025 and 2026: Short term Debt surged 436.65% in 2025, then surged 188.61% in 2026.
• Over 4 years, Short term Debt stood at $3.2 million in 2023, then plunged by 72.92% to $865000.0 in 2024, then soared by 436.65% to $4.6 million in 2025, then gained by 25.03% to $5.8 million in 2026.
• According to Business Quant data, Short term Debt over the past three periods registered $5.8 million, $4.6 million, and $2.4 million for Q1 2026, Q4 2025, and Q3 2025 respectively.